IVD Assay Development
Seraseq® gDNA BRCA1/2 LGR Somatic Mutation Mix
Details
Resources
Specifications
Frequently Asked Questions
LGC Clinical Diagnostics has developed BRCA Reference Materials which include 10 variants in BRCA1 and 10 variants in BRCA2 ranging in size from SNVs to insertions and/or deletions over 500 bp (11 exon-level large rearrangements), resulting in a variety of phenotypic alterations at the amino acid level, including missense, nonsense, frameshift, stop-gain/loss, splice-site, and insertion/deletion of partial or up to two exons (see Product Sheet MKT-00818 for more details).
FEATURES AND BENEFITS•Develop, monitor, validate and challenge your hybrid capture-based targeted NGS assays with confidence using a highly multiplexed reference material containing biomarkers important in BRCA-driven cancers.• Single sample with 20 pathogenic BRCA1/2 variants (11 LGRs, 9 deletions, 5 SNVs, 4 indels, and 2 insertions).• Mutation targets quantitated by highly sensitive dPCR assays, and orthogonally analyzed by NGS.• All mutations are blended against the well-characterized GM24385 human genomic DNA as ‘wildtype’ background material. • Available as full process (FFPE curl) or purified genomic DNA at various allele frequencies suited for either somatic or germline testing.•Manufactured in GMP-compliant and ISO 13485-certified facilities.
Seraseq gDNA BRCA12 LGR Somatic Mutation Mix
Seraseq gDNA BRCA1/2 LGR Somatic Mutation Mix
Seraseq gDNA BRCA1/2 LGR Somatic Mutation Mix
Seraseq gDNA BRCA1 Non-Requirement Letter
Seraseq gDNA BRCA1/2 LGR Somatic Mutation Mix PI
Technical Spreadsheet for Seraseq BRCA 1/2 LGR Reference Materials
Solid Tumor FAQs
Review the common questions we receive from our customers and the responses we provide.